Pharmaron Completes Strategic Investment in LinkStart and Enters into Strategic Partnership Arrangement

Beijing, China, June 18, 2019 — Pharmaron, a global leading life science services company headquartered in Beijing, and LinkStart SMO Ltd. LinkStart, a clinical SMO headquartered in Beijing, announced today that Pharmaron completed a strategic investment and entered into a strategic partnership arrangement with LinkStart, aiming for a sustainable and deep strategic relationship.

LinkStart will become Pharmaron’s strategic partner for clinical development services in China. Both parties will make full use of their complementary strengths in technologies, resources and market access to better serve their partners in the clinical development area. This partnership strengthens Pharmaron’s clinical development service capabilities, which follows the acquisition of its clinical pharmacology center in Baltimore, Maryland in 2017 and the recent acquisition of a majority stake in CR Medicon. This investment facilitates the construction of the end-to-end service platform to support needs from drug discovery through to clinical development and accelerate the clinical development process.  

Mr. Yang Liu, founder, Chairman and CEO of LinkStart, expressed his enthusiasm about this partnership. “LinkStart has been striving to provide high quality clinical SMO services to our partners, in addition to elevating the SMO industry’s standard in China by working closely with clinically relevant parties. We are excited to have Pharmaron, a highly experienced global player in the life science service industry, as our strategic investor and partner. With this strategic partnership, my team and I are confident to realize LinkStart’s long-term strategy, to better serve the life science industry by accelerating the clinical development process for innovative medicines and to become a world-renowned SMO brand.”

Mr. Larry Lou, President and COO of Pharmaron commented, “Our investment in LinkStart strengthens Pharmaron’s clinical development capabilities, which allows Pharmaron to be a step closer to providing fully integrated drug R&D service to our partners. This clinical SMO investment complements our recent strategic move with CR Medicon and together with our clinical pharmacology center and clinical metabolism labs in the USA and UK, we can better support our partners’ clinical development needs both domestically and globally.”

About LinkStart

LinkStart is a privately owned, leading clinical SMO in China. Founded in 2012, headquartered in Beijing, LinkStart has established stable and long term collaboration relationship with over 500 national clinical research centers in China. It has a branch in Nanjing, and business offices in Shanghai, Nanjing, Guangzhou, Hangzhou, Chengdu, Haerbin, Hefei, Wuhan, Xi’an, etc, covering 110+ cities in China. The company has conducted 400+ studies, of which 85% are the 1st class of new drugs and biological products. LinkStart is particularly experienced in conducting clinical research for drugs against cancer, endocrinological diseases, cardiovascular diseases, infection and immune rheumatoid diseases.   

About Pharmaron 

Pharmaron (China’s A-share Market: 300759) is a public-owned, premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of R&D service capabilities ranging from synthetic and medicinal chemistry, biology, DMPK, pharmacology, safety assessment, radiochemistry and radiolabelled metabolism, clinical pharmacology, clinical analytical sciences, chemical & pharmaceutical development to clinical CRO. With over 6,800 employees, and operations in China, the United States, and the United Kingdom, Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China. For more information: www.pharmaron.com